Kaspar von Meyenburg

ImVisioN Therapeutics AG is a Swiss, clinical stage immunotherapy company developing novel treatments to cure allergies. The Company is the pioneer in intralymphatic immunotherapy (ILIT ™), a proprietary technology for the delivery of immunotherapeutics in the treatment of allergies. ILIT ™ is clinically proven and has been shown to be a safer, more efficacious and more convenient means of delivering allergy therapeutics. By applying another proprietary technology, Modular Antigen Transportation ™ (MAT ™), ImVisioN leverages the potential of ILIT ™ to develop drugs that use allergens safely for specific and highly effective antigen presentation. ImVisioN's lead product is for the treatment of cat dander allergy and the Company has programs addressing birch pollen and house dust mite allergies. The Company's proprietary technology platforms are applicable to further allergy targets, which may be addressed in the future.

Ciba Holding AG manufactures and markets chemicals that provide color, performance and care for plastics, coatings, textile, paper, home & personal care and other products. The firm provides services to the plastic, rubber, adhesives lubricant, home and personal care, coatings, graphic arts, electronic, detergents and hygiene industries. It operates through four segments Plastic Additives, Coating Effects, Water & Paper Treatment and Textile Effects. The company has offices in Europe, America and Asia. Ciba Holding was founded on April 24, 1996 and is headquartered in Basel, Switzerland.